The Cuban enterprise Cimab S.A. and Neuronic Mexicana S.A. establish a new company named IncuBIO, with headquarters in the Mariel Special Development Zone.

A new joint venture for the development and commercialization of innovative biotechnology products has been established in the Mariel Special Development Zone, named IncuBIO S.A., according to an announcement made by the Cuba’s Cimab S.A. and Neuronic Mexicana S.A. de C.V.

Information on the Ministry of Foreign Trade and Investment (Mincex) website indicates that IncuBIO is designed to attract venture capital, and its shares may be acquired by future investors, looking to increase the value of products by financing clinical trials in markets of underdeveloped countries.

Cuba initiates WHO prequalification of its vaccines

Among the innovative products for which development and commercialization rights are granted by the exclusive license from the new entity is NeuroEPO, one of the most promising assets in the portfolio of the Center for Molecular Immunology, since it is being tested as a treatment for several neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Ataxia.

Delta is responsible for increased transmission in Cuba, while vaccines contain impact

The Mincex publication details that, with the incorporation of IncuBIO, Cimab – dedicated to the development and management of businesses through its direct participation in international alliances – is a shareholder in five joint ventures located in China, Thailand, Singapore and Cuba.

Despite worldwide opposition, Biden extends law sustaining the blockade

Neuronic Mexicana S.A. de C.V. will be responsible for the commercialization of biopharmaceutical products and medical equipment.